| Issue 1 - 2013 |
Passion & Means • Q&A: Dr. Neil Kay • Green Tea Update • CLL Research Wish List • New Projects |
| Issue 2 - 2012 |
MD Anderson Moon Shot • Summer Alliance Meeting • Expanding Collaborations • Targeted Treatments • Letter Writing Campaign • Grant Project Updates |
| Issue 1 - 2012 |
Chronic versus acute • Immunotherapy • Q&A: Dr. Stephan Stilgenbauer • New projects • Partnership opportunities |
| Issue 2 - 2011 |
Significance of historical information • Chimeric Antigen Receptors (CARs) • Q&A: Dr. Laurence Cooper • Bruton's tyrosine kinase • Partner Perspective: Will Newman |
| Issue 1 - 2011 |
Global collaborations • Alliance meeting • MicroRNAs • Q&A: Dr. George Calin • p53 • Stem cell transplant • Creative giving |
| Holiday 2010 |
Philanthropy will cure CLL • Mouse models • Signal transduction inhibitors • CLL in the elderly • Patient symposium • Prognostic factors • Cord blood transplant |
| Summer 2010 |
State of CLL research • CLL Global’s history • Alliance meeting • Alliance collaborations • Researchers in the background • Projects reach clinic |
| Spring 2010 |
Genetics • Personalized therapy • Epstein-Barr virus • Clinical trial introduction • New projects |
| Fall
2009 |
Targeting ROR1 • CLL pathways • Relapsed CLL • Stem cell transplant introduction • Beyond FCR • Genetics • Skin cancer • TCL1 |
| Summer
2009 |
Investing in CLL research • Genetics • FCR data • Microbead technology |
| Winter
2008 |
How will CLL be cured? • Q&A: Dr. Emil J Freireich • Alliance update • 8-chloro-adenosine • New drugs • Secondary cancers • Flu shots • Ripple effect of grants |
| Summer
2008 |
Alliance introduction • Targeting proteins • Cellular signals • Alliance meeting • Minimal residual disease • CLL immunity collaboration • Immune system education • Proactive patient |
| Fall
2007 |
CLL microenvironment • Cure CLL now • Stat-3 • Single nucleotide polymorphisms • TCL1 • Alemtuzumab • Heavy water |
| Spring
2007 |
Familial CLL • Prognostic factors • Educating T-cells • Mapping genes • Gene modification • ZAP-70 • CD38 |
| Fall
2006 |
Gene therapy studies • Initial grants • Green tea • Glycolycin • 8-chloro-adenosine • Protein expression • Indolent or aggressive CLL |
Tidbits is a lighter take on the happenings in the CLL research community. Click below to catch up previous issues or to sign up to receive Tidbits.
View the Tidbits Archive
Read CLL Research Momentum to stay informed about projects we are funding and progress made in the fight against CLL. 